Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2003Journal of Antimicrobial Chemotherapy

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

View Full Paper
Ask AI
Bookmark
Share

Authors

XLX. LiThe University of Texas Health Science Center at San Antonio

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

X. Li (2003) studied this question.

synapsesocial.com/papers/6aaa20ff43aa24511284420bhttps://doi.org/10.1093/jac/dkh027
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation1997 · 359 citations
  2. 2National Committee for Clinical Laboratory Standards1980 · 14,792 citations
  3. 3Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility1995 · 204 citations
  4. 4Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus1997 · 620 citations
  5. 5In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp2002 · 232 citations